אלצהיימר ודמנציות אחרות | רחל ברנבאום עורכת

הטיפול והתמודדות המטפלים עם תשושי נפש בקהילה 22 Holmes, C., Boche, D., Wilkinson, D., Yadigarfar, G., Hopkins, C., Bayer, A.C., Jones, R.W. et al. (2008). Long-term effects of Abeta 42 immunisation in Alzheimer’s disease: Follow-up of a randomized, placebo-controlled phase 1 trial. Lancet , 372:316-23. Johannsen, P. (2004). Long-term cholinesterase inhibitor treatment of Alzheimer’s disease. CNS Drugs , 18: 757-68. Langa, K.D., Foster, N.L. & Larson, E.B. (2004). Mixed dementia: Emerging concepts and therapeutic implications. JAMA , 292: 2901-2908. Lipton, S.A. (2004). Paradigm shift in NMDA receptor antagonist drug development: Molecular mechanism of uncompetitive inhibition by Memantine [Ebixa] in the treatment of Alzheimer’s disease and other neurological disorders. Journal of Alzheimer’s Disease , 6 6 (Suppl) 61-74. Lopez, O.L., Becker, J.T., Wisniewski, S. et al. (2002). Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. Journal of Neurology Neurosurgery Psychiatry , 72: 310-314. McKeith, I., Del Ser, T., Spano, P. et al. (2000). Efficacy of Rivastigmine in dementia with Lewy Bodies: A randomized, double-blind, placebo- controlled international study. Lancet , 356: 2031-6. Mohs, R.C., Rosen, W.G. & Davis, K.L. (1983). The Alzheimer Disease Assessment Scale. Psychopharmacological Bulletin , 19:448-50. Nobili, F. et al. (2002). Brain perfusion follow-up in Alzheimer patients during treatment with Acetylcholinesterase inhibitors. J ournal of Nuclear Medicine , 43: 983-90. Passmore, A.P., Bayer, A.J. & Steinhagen-Thiessen, E. (2005). Cognitive, global, and functional benefits of Donepezil [Aricept, Memorit] in Alzheimer disease and Vascular Dementia: Results from large-scale clinical trials. Journal of the Neurological Sciences , 229-230: 141-6. Reisberg, B., Doody, R., Stoffler, A. et al. (2003). Memantine [Ebixa] in moderate-to severe Alzheimer’s disease. Journal of Medicine , 348: 1333-41. Reisberg, B., Ferris, S.H., de Leon, M.J. et al. (1982). The global deterioration scale for assessment of primary degenerative dementia. American Journal of Psychiatry , 139: 1136-9.